Compugen (CGEN) has released an update.
Compugen Ltd., a clinical-stage immunotherapy company, has provided updates for Q1 2024, announcing completed enrollment for their ovarian cancer study, with data expected in Q4. They are also preparing to present findings on colorectal cancer at the upcoming ASCO meeting and are advancing towards a Phase 1 study for their new drug COM503. AstraZeneca’s progression of rilvegostomig to Phase 3 trials for nonsquamous NSCLC could mean future milestone payments for Compugen, whose strong financial position is anticipated to fund operations into 2027.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
